Buy Cararthron®
Cararthron® is available from your local pharmacy or healthfood store. Stockists include:
We are delighted to have Health Station as distributor for New Zealand customers:
Chalmers Dale & Co. Pty. Ltd. is a privately owned Australian biotech company based in Sydney, Australia and a supplier of health and nutrition products to Australia and the world.
Cararthron® is manufactured by Chalmers Dale & Co. Pty Ltd
Suite 1530, 30 Glen St, Milsons Pt., NSW 2061 Australia
Cararthron® helps provide relief of pain and stiffness associated with osteoarthritis and rheumatoid arthritis. Each capsule contains 250mg UNIVESTIN™ a proprietary patented blend of:
• Scutellaria Baicalensis root extract equiv to dry root 2500mg
• Acacia Catechu herb extract dry concentrate equivalent to dry heartwood 715mg
These herbs have both been used traditionally in oriental and ayurvedic medicine for their anti-inflammatory properties.
Cararthron® has been clinically tested and found that regular intake over 4-12 weeks resulted in an improvement of mobility and reduction in stiffness at a level equivalent to that demonstrated by conventional therapies.
Directions for use:
Adults: Take 1 or 2 capsules daily with meals or as directed by your practitioner. Not suitable for children. Store below 30°C.
Univestin™ is a Trade Mark owned by Unigen Inc.
U.S. Patent No. 7,108,868 U.S. Patent No. 7,192,611
‘Mountain from Sky’ image by Dino Olivieri / CC BY 2.0 | Image of Acacia Catechu flowers by J.M.Garg / CC BY SA 3.0
Disclaimer
Please note that this website (http://www.cararthron.com.au) is intended to be an information source for Cararthron®, and its content should not be construed as medical advice. For medical advice about osteoarthritis and rheumatoid arthritis, please consult your physician.
Cararthron® helps provide relief of pain and stiffness associated with osteoarthritis and rheumatoid arthritis. Cararthron® is a medical food product for the nutritional management of osteoarthritis. It is not a drug product to treat, cure or prevent osteoarthritis.
Cararthron® has been clinically tested and found that regular intake over 4-12 weeks resulted in an improvement of mobility and reduction in stiffness at a level equivalent to that demonstrated by conventional therapies. While Cararthron® is safe for daily use and has been extensively tested and has shown an excellent safety profile, it is possible that some people using it may have an adverse reaction. If you or anyone you know has an adverse reaction to Cararthron®, please consult your physician and report this case to us, via the Contact section of this website.
Cararthron® has not been tested for use by pregnant or nursing women or children. Cararthron® is not an NSAID or COX-2 inhibitor.